AbbVie Inc. (ABBV) — closed signal from September 11, 2025
Target reached Published before the outcome was known, scored automatically when the window closed on December 10, 2025.
Predicted vs. what happened
What happened
Reached its target in 20 days.
The thesis — published September 11, 2025
AbbVie is a short-term idea driven by market mood. A news burst lifted the stock 5.37% before the open, showing strong interest. But possible US limits on China-invented drugs could hurt future products. Interest looks firm, yet a key chart read points down and the core story is mixed. Plan: buy only on dips, wait for proof of a 0-3 month rebound, and watch policy headlines closely. This keeps risk controlled while staying open to a quick bounce.
Primary drivers
- Strong recent interest; many traders favor it for short-term moves
- Early jump before the open suggests unusual, active buyer interest
- Possible US rules could hurt drugs sourced from China partners
- Chart signals are cautious, so waiting for clearer strength makes sense
How it played out
ABBV: target reached in 20 days
Lyra published ABBV on 2025-09-11 as a short-term idea at $217.39, with expected growth of 11%. The thesis pointed to firm short-term interest, a 5.4% jump before the open, possible US limits on China-invented drugs, and cautious chart signals. It called for patience on dips and proof of a 0-3 month rebound.
Inside the window, the stock reached $243.06 on 2025-10-01. That was above the $239.57 target, with a peak gain of 11.8%, and it happened in 20 days. By 2025-12-10, ABBV ended at $225.18. The thesis played out.
What happened during the window
On 2025-10-31, AbbVie reported third-quarter 2025 revenue of $15.78 billion and adjusted earnings of $1.86 per share. The company also raised full-year adjusted earnings guidance to $10.61-$10.65 per share.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.